Neosar
Showing 1 - 25 of 387
Lymphoma, Large B-Cell, Diffuse Trial (Cyclophosphamide, TLI, Fludarabine)
Not yet recruiting
- Lymphoma, Large B-Cell, Diffuse
- Cyclophosphamide
- +2 more
- (no location specified)
Aug 18, 2023
DLBCL - Diffuse Large B Cell Lymphoma Trial in Toronto (Cyclophosphamide, TLI)
Recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- Cyclophosphamide
- TLI
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 19, 2023
Follicular Lymphoma Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate)
Not yet recruiting
- Follicular Lymphoma
- Axicabtagene Ciloleucel
- +5 more
- (no location specified)
Sep 21, 2023
Solid Tumors Trial in Houston (Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate)
Not yet recruiting
- Solid Tumors
- Rimiducid
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Sep 27, 2023
Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)
Not yet recruiting
- Myeloma
- Fludarabine phosphate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 27, 2023
Head Neck Cancer, Relapse, Recurrent Trial in Chapel Hill (Cyclophosphamide, Fludarabine, Cell Therapy)
Not yet recruiting
- Head and Neck Cancer
- +3 more
- Cyclophosphamide
- +2 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Oct 18, 2023
Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)
Not yet recruiting
- Synovial Sarcoma
- Fludarabine phosphate
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia) Trial run by the National Heart, Lung, and Blood Institute
Active, not recruiting
- Small Lymphocytic Lymphoma
- CLL (Chronic Lymphocytic Leukemia)
- Fludarabine Phosphate
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 13, 2022
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Boston (Eribulin, Adriamycin,
Active, not recruiting
- Inflammatory Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Eribulin
- +2 more
-
Boston, Massachusetts
- +1 more
Nov 28, 2022
Lymphoma Trial in Houston (2CdA, Cyclophosphamide, Rituximab)
Completed
- Lymphoma
- 2CdA
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Mar 3, 2022
Tumor, Metastatic Melanoma, Melanoma Trial in Houston (OBX-115, Acetazolamide, Cyclophosphamide)
Not yet recruiting
- Tumor
- +2 more
- OBX-115
- +5 more
-
Houston, TexasMD Anderson Cancer Center
Aug 16, 2022
Hematological Malignancy Trial in Houston (Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells)
Not yet recruiting
- Hematological Malignancy
- Fludarabine Phosphate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)
Completed
- Breast Cancer
- Panitumumab
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 20, 2022
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in Seattle (Autologous Mesothelin-specific
Recruiting
- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8
- Autologous Mesothelin-specific TCR-T Cells
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 31, 2023
Non Hodgkin Lymphoma Trial in Cleveland (UF-KURE19 CAR-T cells, Fludarabine, Cyclophosphamide)
Recruiting
- Non Hodgkin Lymphoma
- UF-KURE19 CAR-T cells
- +2 more
-
Cleveland, Ohio
- +1 more
Nov 21, 2022
Soft Tissue Sarcoma, Bone Sarcoma Trial in Houston (Cyclophosphamide, attIL2-T cells)
Not yet recruiting
- Soft Tissue Sarcoma
- Bone Sarcoma
- Cyclophosphamide
- attIL2-T cells
-
Houston, TexasM D Anderson Cancer Center
Nov 10, 2022
Leukemia Trial in Portland (cyclophosphamide, cytarabine, dexamethasone)
Terminated
- Leukemia
- cyclophosphamide
- +8 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 13, 2022
Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma Trial in Houston (CAR.70/IL15-transduced CB-derived
Not yet recruiting
- Advanced Renal Cell Carcinoma
- +2 more
- CAR.70/IL15-transduced CB-derived NK cells
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2023
Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma Trial in Tampa (TBio-4101, Cyclophosphamide, Fludarabine)
Recruiting
- Metastatic Melanoma
- +9 more
- TBio-4101
- +3 more
-
Tampa, FloridaMoffitt Cancer Center
Jan 24, 2023
Tumor Trial in Houston (SGT-53, Topotecan, Cyclophosphamide)
Suspended
- Neoplasm
- SGT-53
- +2 more
-
Houston, TexasTexas Children's Hospital
Feb 7, 2022
Lymphoma, Mantle Cell Lymphoma Trial in Houston (Acalabrutinib, Rituximab, Brexucabtagene Autoleucel)
Not yet recruiting
- Lymphoma
- Mantle Cell Lymphoma
- Acalabrutinib
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Aug 10, 2022
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders Trial in Chapel Hill (iC9-CAR19 cells,
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- iC9-CAR19 cells
- +3 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 21, 2022